Global Contract Manufacturing Market for Biologics (up to 2027): By Product, By Platform, By Therapeutic Area, By Region
360iResearch predicts that the global contract manufacturing market for biopharmaceuticals, which was valued at $16.92 billion in 2021, will reach $19.64 billion in 2022 and expand to $41.92 billion by 2027, growing at a CAGR of 16.32%. This research report analyzes the global market for biopharmaceutical contract manufacturing from multiple perspectives, including an introduction, research methodology, executive summary, market overview, market insights, product analysis (biosimilars, insulin, interferons, monoclonal antibodies, recombinant hormones), platform analysis (mammalian, microbial), therapeutic area analysis (autoimmune diseases, cardiovascular diseases, infectious diseases, metabolic diseases, neurological diseases), regional analysis (North and South America, the United States, Canada, Brazil, Asia-Pacific, Japan, China, India, South Korea, Taiwan, Europe/Middle East/Africa, the United Kingdom, Germany, France, Russia, and others), competitive landscape, and company information.
